06/05
Headlines

NASDAQ:ACHN

Biotech unusual volume stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), BioDelivery Sciences International (NASDAQ:BDSI), ImmunoCellular Therapeutics (NYSEMKT:IMUC), Anika Therapeutics (NASDAQ:ANIK)

Jason Knox03 mins

AbbVie may now consider a takeover of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), a $411 million company, to expand in that market, Redmond said. Shares of Achillion rallied (ACHN:US) as much as 67 percent yesterday. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was 47.57% in last session and finished the day at $4.25. Traded volume was 47.79million shares…

Read More

Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Mark DeFrance03 mins

Insys Therapeutics, Inc. (NASDAQ:INSY)’s shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was -15.70% in last session and finished the day at $23.01. Traded volume was 3.24million…

Read More

Healthcare Losers: Cytokinetics (NASDAQ:CYTK), Achillion Pharmaceuticals (NASDAQ:ACHN), Pharmacyclics (NASDAQ:PCYC), Organovo Holdings Inc (NYSEMKT:ONVO)

Kristen Barton02 mins

Cytokinetics, Inc. (NASDAQ:CYTK) announced disappointing top-line results from its BENEFIT-ALS midstage study involving tirasemtiv. Tirasemtiv did not meet its primary efficacy endpoint of delivering a mean change from baseline in the ALS functional rating scale. Cytokinetics, Inc. (NASDAQ:CYTK) stock performance was -64.67% in last session and finished the day at $4.59. Traded volume was 17.26million…

Read More

Biotech Bearish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Galena Biopharma (NASDAQ:GALE), Insmed Incorporated (NASDAQ:INSM), CytRx Corporation (NASDAQ:CYTR)

Kristen Barton02 mins

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm currently has a $6.00 price target on the stock. Maxim Group’s target price would suggest a potential upside of 62.16% from the stock’s…

Read More

Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Mark Doerr02 mins

Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume…

Read More

Big Moves in Focus: China Finance Online Co. (ADR) (NASDAQ:JRJC), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Intrexon (NYSE:XON), JetBlue Airways (NASDAQ:JBLU), VeriFone Systems (NYSE:PAY)

Adam Keintzel02 mins

On Jan. 5, China Finance Online Co. (ADR) (NASDAQ:JRJC), successfully hosted “Leading China 2014: Financial Industry Innovation Forum” on December 25, 2014 at China World Hotel in Beijing. China Finance Online Co. (ADR) (NASDAQ:JRJC) belongs to Technology sector. Its net profit margin is -9.80% and weekly performance is -4.05%. On last trading day company shares…

Read More